【藥品性質提示】 根據 2019 AGS Beers Criteria，本藥品為【潛在不適當用藥 (PIM)】，不建議老年人使用 >325mg/day。

抗血小板口服 Atrial fibrillation (Prophylaxis of thromboembolic disorder), Carotid artery stenosis, Cerebrovascular accident, Disorder of cardiovascular system, Myocardial infarction, Headache, Fever, Percutaneous coronary intervention

【備註】 川崎病（Kawasaki Disease）之使用為臨床指引建議用途（AHA 2024, JCS/JSPCCS 2020），屬醫囑使用（off-label），請依兒科專科醫師指示使用。 劑量依病程階段調整：急性期30–50 mg/kg/day，恢復期3–5 mg/kg/day。

Aspirin is a more potent inhibitor of both prostaglandin synthesis and platelet aggregation than its other salicylic derivatives due to the acetyl group on the aspirin molecule, which irreversibly inactivates cyclooxygenase via acetylation [28]. This prevents the conversion of arachidonic acid to thromboxane A(2). Platelet aggregation is inhibited for their lifespan of 7 to 10 days.

Elimination Half Life: 20 to 60 minutes

Hypersensitivity to NSAIDs.
Syndrome of asthma, rhinitis, and nasal polyps; severe urticaria, angioedema, or bronchospasm may occur.

Fetal risk can not be ruled out.

Avoided.

GI upset.

Usual oral dose: 75-325mg daily

川崎病（Kawasaki Disease）之使用為臨床指引建議用途（AHA 2024, JCS/JSPCCS 2020），屬醫囑使用（off-label），請依兒科專科醫師指示使用。
劑量依病程階段調整：急性期30–50 mg/kg/day，恢復期3–5 mg/kg/day。

Renal impairment, severe (GFR<10 mL/min): Avoid use

Hepatic impairment, severe: Avoid use